# US 2026/0217695 A1 · Methods for synthesis of chk1 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0217695 A1
- Document ID: US20260217695A1
- Status: Published application
- Kind: A1
- Application number: 19/573,479
- Filed: 2026-03-20
- Published: 2026-07-30
- Earliest claimed: 2020-04-07
- Assignees: CRT Pioneer Fund LP
- Applicants: CRT Pioneer Fund LP
- Inventors: Michael Schwaebe; Thorsten Rosner; Dalian Zhao; Ross Miller; Rich Dulina; Michael Humora; Stephen E. Gottschling
- Web page: https://patentgrep.com/patent/US20260217695A1

## CPC

- C07D 413/14: containing three or more hetero rings
- C07C 59/265: Citric acid
- C07D 265/30: not condensed with other rings
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present technology relates to processes, compounds, compositions, and methods useful for coupling reactions. Also, the present disclosure provides for novel intermediates, compositions of matter, and processes relating to the Chk1 inhibitor, SRA737.

## Claims

### Claim 1

A compound of formula I:
wherein R1 is selected from: C1-12 alkyl, substituted C1-12 alkyl, C1-12 alkenyl, substituted C1-12 alkenyl, C1-12 alkynyl, substituted C1-12 alkynyl, C1-12 alkoxy, substituted C1-12 alkoxy, C3-8 cycloalkyl, substituted C3-8 cycloalkyl, C3-8 heterocycloalkyl, substituted C3-8 heterocycloalkyl, C1-12 amino, C1-12 substituted amino, phenyl, substituted phenyl, C3-8 heteroaryl, and substituted C3-8 heteroaryl;
and wherein the compound is a dimethylformamide (DMF) solvate.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is C1-12 alkoxy or substituted C1-12 alkoxy.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R1 is C1-12 alkyl or substituted C1-12 alkyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is C3-8 heterocycloalkyl or C3-8 heteroaryl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R1 is —OC(CH3)3.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5 which is substantially purified and is crystalline.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A pharmaceutical composition comprising a compound according to any one of claims 1-6, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer and/or N-oxide thereof, and at least one pharmaceutically acceptable carrier or excipient.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 1 mol % of one or more palladium compounds as impurities.

### Claim 9 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.5 mol % of one or more palladium compounds as impurities.

### Claim 10 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.1 mol % of one or more palladium compounds as impurities.

### Claim 11 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.05 mol % of one or more palladium compounds as impurities.

### Claim 12 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.01 mol % of one or more palladium compounds as impurities.

### Claim 13 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.005 mol % of one or more palladium compounds as impurities.

### Claim 14 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.001 mol % of one or more palladium compounds as impurities.

### Claim 15 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 1 mol % of one or more organic compounds as impurities.

### Claim 16 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.5 mol % of one or more organic compounds as impurities.

### Claim 17 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.1 mol % of one or more organic compounds as impurities.

### Claim 18 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.05 mol % of one or more organic compounds as impurities.

### Claim 19 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.01 mol % of one or more organic compounds as impurities.

### Claim 20 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.005 mol % of one or more organic compounds as impurities.

### Claim 21 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.001 mol % of one or more organic compounds as impurities.

### Claim 22 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 1 mol % of one or more organic compounds and one or more palladium compounds all together as impurities.

### Claim 23 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.5 mol % of one or more organic compounds and one or more palladium compounds all together as impurities.

### Claim 24 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.1 mol % of one or more organic compounds and one or more palladium compounds all together as impurities.

### Claim 25 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.05 mol % of one or more organic compounds and one or more palladium compounds all together as impurities.

### Claim 26 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.01 mol % of one or more organic compounds and one or more palladium compounds all together as impurities.

### Claim 27 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.005 mol % of one or more organic compounds and one or more palladium compounds all together as impurities.

### Claim 28 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition comprises no more than 0.001 mol % of one or more organic compounds and one or more palladium compounds all together as impurities.

### Claim 29 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The pharmaceutical composition of any one of claims 7-28, wherein the composition is formulated for parenteral administration.

### Claim 30 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The pharmaceutical composition of any one of claims 7-28, wherein the composition is formulated for intravenous administration.

### Claim 31 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The pharmaceutical composition of any one of claims 7-28, wherein the composition is formulated for subcutaneous administration.

### Claim 32 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The pharmaceutical composition of any one of claims 7-28, wherein the composition is formulated for enteral administration.

### Claim 33 (depends on 32)

The pharmaceutical composition of claim 32, wherein the composition is formulated for oral administration.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6)

A process for preparing the solvate of any one of claims 1-6, the process comprising crystallizing the solvate from a mixture comprising the compound of formula I, water and dimethylformamide (DMF).

### Claim 35

A crystalline solid form of a compound of formula H:

### Claim 36 (depends on 35)

The solid form of claim 35 having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 12.9°, about 18.1°, about 20.6°, about 21.6°, about 22.3° about 26.5°, and 27.8°.

### Claim 37 (depends on 35)

The solid form of claim 35 having an X-ray powder diffraction pattern substantially as shown in FIG. 2.

### Claim 38 (depends on 35, 36, 37)

The solid form of any one of claims 35-37 having a differential scanning calorimetry (DSC) thermogram comprising an endothermic peak at about 215.1° C.

### Claim 39 (depends on 35, 36, 37, 38)

The solid form of any one of claims 35-38 having a differential scanning calorimetry (DSC) thermogram substantially as shown in FIG. 3.

### Claim 40 (depends on 35, 36, 37, 38, 39)

The solid form of any one of claims 35-39 having a thermogravimetric analysis (TGA) substantially as shown in FIG. 4.

### Claim 41 (depends on 35, 36, 37, 38, 39, 40)

The solid form of any one of claims 35-40 which is substantially purified.

### Claim 42

A crystalline solid form of a compound of formula VIII:

### Claim 43 (depends on 42)

The solid form of claim 42 having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 7.8°, about 10.5°, about 12.1°, about 16.0°, about 16.8°, about 17.0°, about 17.7°, about 18.0°, about 20.5°, about 21.0°, about 21.9°, about 24.3°, about 25.2°, about 26.1° 1, about 27.0°, about 32.3°, and about 36.0°.

### Claim 44 (depends on 42)

The solid form of claim 42 having an X-ray powder diffraction pattern substantially as shown in FIG. 6.

### Claim 45 (depends on 42, 43, 44)

The solid form of any one of claims 42-44 which is substantially purified.

### Claim 46

A crystalline solid form of a compound salt of formula IX:

### Claim 47 (depends on 46)

The solid form of claim 46 having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 5.9°, about 11.3°, about 11.8°, about 14.5°, about 14.8°, about 17.8°, about 18.4°, about 18.7°, about 19.0°, about 19.3°, about 20.2°, about 20.6°, about 20.9°, about 21.2°, about 21.7°, about 23.0°, about 23.7°, about 24.0°, about 24.4°, and about 24.7°.

### Claim 48 (depends on 46)

The solid form of claim 46 having an X-ray powder diffraction pattern substantially as shown in FIG. 7.

### Claim 49 (depends on 46, 47, 48)

The solid form of any one of claims 46-48 which is substantially purified.

### Claim 50

A crystalline solid form of a compound of formula X:

### Claim 51 (depends on 50)

The solid form of claim 50 having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 5.6°, about 11.1°, about 14.8°, about 16.7°, about 19.0°, about 19.4° about 24.4°, and about 28.0°.

### Claim 52 (depends on 50)

The solid form of claim 50 having an X-ray powder diffraction pattern substantially as shown in FIG. 5.

### Claim 53 (depends on 50, 51, 52)

The solid form of any one of claims 50-52 which is substantially purified.

### Claim 54 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

A pharmaceutical composition comprising a compound or a solid according to any one of claims 35 to 53, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer and/or N-oxide thereof, and at least one pharmaceutically acceptable carrier or excipient.

### Claim 55 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 1 mol % of one or more palladium compounds as impurities.

### Claim 56 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.5 mol % of one or more palladium compounds as impurities.

### Claim 57 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.1 mol % of one or more palladium compounds as impurities.

### Claim 58 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.05 mol % of one or more palladium compounds as impurities.

### Claim 59 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.01 mol % of one or more palladium compounds as impurities.

### Claim 60 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.005 mol % of one or more palladium compounds as impurities.

### Claim 61 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.001 mol % of one or more palladium compounds as impurities.

### Claim 62 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 1 mol % of one or more organic compounds as impurities.

### Claim 63 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.5 mol % of one or more organic compounds as impurities.

### Claim 64 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.1 mol % of one or more organic compounds as impurities.

### Claim 65 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.05 mol % of one or more organic compounds as impurities.

### Claim 66 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.01 mol % of one or more organic compounds as impurities.

### Claim 67 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.005 mol % of one or more organic compounds as impurities.

### Claim 68 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.001 mol % of one or more organic compounds as impurities.

### Claim 69 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 1 mol % of one or more organic compounds and one or more palladium compounds all together as impurities.

### Claim 70 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.5 mol % of one or more organic compounds and one or more palladium compounds all together as impurities.

### Claim 71 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.1 mol % of one or more organic compounds and one or more palladium compounds all together as impurities.

### Claim 72 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.05 mol % of one or more organic compounds and one or more palladium compounds all together as impurities.

### Claim 73 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.01 mol % of one or more organic compounds and one or more palladium compounds all together as impurities.

### Claim 74 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.005 mol % of one or more organic compounds and one or more palladium compounds all together as impurities.

### Claim 75 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises no more than 0.001 mol % of one or more organic compounds and one or more palladium compounds all together as impurities.

### Claim 76 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The pharmaceutical composition of any one of claims 54-75, wherein the composition is formulated for parenteral administration.

### Claim 77 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The pharmaceutical composition of any one of claims 54-75, wherein the composition is formulated for intravenous administration.

### Claim 78 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The pharmaceutical composition of any one of claims 54-75, wherein the composition is formulated for subcutaneous administration.

### Claim 79 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The pharmaceutical composition of any one of claims 54-75, wherein the composition is formulated for enteral administration.

### Claim 80 (depends on 79)

The pharmaceutical composition of claim 79, wherein the composition is formulated for oral administration.

### Claim 81

A process to manufacture a compound of formula VII:
the process comprising
a) coupling a compound of formula V:
with the compound of formula VI:
under cross coupling reaction conditions to provide the compound of formula VII;
b) crystallizing and isolating the compound of formula VII from the mixture;
wherein Pg is an organic group that is an amino protecting group and LvG is an organic group that is a leaving group.

### Claim 82 (depends on 81)

The process of claim 81, wherein the process further comprises:
a) providing a first mixture comprising the compound of formula V, the compound of formula VI, a catalyst, a ligand, and DMF;
b) providing a second mixture comprising an inorganic base and DMF, wherein the second mixture has been heated to between about 125-135° C.;
c) combining the first mixture with the second mixture to provide a third mixture, wherein the temperature of the third mixture is maintained at between about 125-135° C.

### Claim 83 (depends on 82)

The process of claim 82, wherein Pg is a C1-12 alkoxycarbonyl or substituted C1-12 alkoxycarbonyl protecting group.

### Claim 84 (depends on 82)

The process of claim 82, wherein Pg is C1-12 alkylcarbonyl or substituted C1-12 alkylcarbonyl protecting group.

### Claim 85 (depends on 82)

The process of claim 82, wherein Pg is
(tert-butoxycarbonyl or Boc group).

### Claim 86 (depends on 82)

The process of claim 82, wherein a palladium compound is used for the cross coupling reaction conditions.

### Claim 87 (depends on 82)

The process of claim 82, wherein a copper compound is used for the cross coupling reaction conditions.

### Claim 88 (depends on 86)

The process of claim 86, wherein the cross coupling reaction conditions comprise a palladium compound, an organophosphorus compound, an inorganic base, and an organic solvent.

### Claim 89 (depends on 88)

The process of claim 88, wherein the palladium compound is a Pd(H) compound.

### Claim 90 (depends on 89)

The process of claim 89, wherein the palladium compound is a Pd(OAc)2 and the organophosphorus compound is (R)-1-[(SP)-2-(Dicyclohexylphosphino)ferrocenyl]ethyldi-tert-butylphosphine.

### Claim 91 (depends on 90)

The process of claim 90, wherein the inorganic base is K3PO4.

### Claim 92 (depends on 91)

The process of claim 91, wherein the organic solvent is a polar aprotic organic solvent.

### Claim 93 (depends on 92)

The process of claim 92, wherein the polar aprotic organic solvent is dimethylformamide (DMF).

### Claim 94 (depends on 88, 89, 90, 91, 92, 93)

The process of any one of claims 88-93, wherein the amount of palladium is no more than 0.3 mol %.

### Claim 95 (depends on 88, 89, 90, 91, 92, 93)

The process of any one of claims 88-93, wherein the amount of palladium is no more than 0.25 mol %.

### Claim 96 (depends on 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The process of any one of claims 81-95, wherein water is added to the reaction mixture to crystallize the compound of formula VII.

### Claim 97 (depends on 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The process of any one of claims 81-96, wherein the compound of formula V is

### Claim 98 (depends on 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The process of any one of claims 81-97, wherein LvG is chlorine.

### Claim 99

A process to manufacture the compound of formula VIII:
the process comprising:
a) coupling the compound of formula III:
with the compound of formula II:
to provide the compound of formula XII:
b) coupling the compound of formula XII:
with the compound of formula VI:
under cross coupling reaction conditions to provide the compound of formula X:
c) crystallizing and isolating the compound of formula X from the mixture;
d) subjecting the compound of formula X to deprotection conditions to provide the compound of formula VIII.

### Claim 100 (depends on 99)

The process of claim 99, wherein the process further comprises:
d) providing a first mixture comprising the compound of formula XII, the compound of formula VI, a catalyst, a ligand, and DMF;
e) providing a second mixture comprising an inorganic base and DMF, wherein the second mixture has been heated to between about 125-135° C.;
f) combining the first mixture with the second mixture to provide a third mixture, wherein the temperature of the third mixture is maintained at between about 125-135° C.

### Claim 101 (depends on 99)

The process of claim 99, wherein the deprotection conditions comprise contacting the compound of formula X with trimethylsilyl iodide (TMSI) in acetonitrile.

### Claim 102

A process to manufacture the compound salt of formula IX:
the process comprising:
a) providing a first mixture comprising the compound of formula VIII:
acetic acid, water, and an alcohol;
b) combining the first mixture with citric acid to provide a second mixture;
c) crystallizing and isolating the compound salt of formula IX:
from the second mixture.

### Claim 103 (depends on 102)

The process of claim 102, wherein the first mixture is prepared by combining the compound of formula VIII, acetic acid, water and an alcohol at about 30-45° C.

### Claim 104 (depends on 103)

The process of claim 103, wherein the second mixture is prepared by combining the first mixture with citric acid at about 20-25° C.

### Claim 105 (depends on 102, 103, 104)

The process of any one of claims 102-104, wherein the alcohol is selected from the group consisting of methanol, ethanol, propanol, butanol, pentanol, tert-butanol, and isopropanol.

### Claim 106 (depends on 105)

The process of claim 105, wherein the alcohol is ethanol.
